Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

March 30, 2022

Study Completion Date

October 3, 2023

Conditions
LymphopeniaMalignant Glioma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

NT-I7

Given IM

OTHER

Placebo

Given IM

Trial Locations (10)

10021

Memorial Sloan-Kettering Cancer Center, New York

15232

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh

19104

Abrams Cancer Center of the University of Pennsylvania, Philadelphia

21231

Johns Hopkins Oncology Center, Baltimore

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

48202

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

63110

Washington University, St Louis

35294-3410

UAB Comprehensive Cancer Center, Birmingham

02215

Dana Farber Cancer Institute, Boston

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

NeoImmuneTech

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER